Evidence map›Paper›PMID 39456660›Full record

ArticleInternational journal of molecular sciences2024

An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.

Laura A Szafron, Piotr Sobiczewski, Agnieszka Dansonka-Mieszkowska, Jolanta Kupryjanczyk, Lukasz M Szafron

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura A SzafronMaria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-7542-3898
Piotr SobiczewskiDepartment of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Agnieszka Dansonka-MieszkowskaCancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Jolanta KupryjanczykDepartment of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Lukasz M SzafronMaria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-1670-0274

Funding

Jakub Count Potocki Foundation 657/19National Science Center 2020/37/B/NZ5/04215The Maria Sklodowska-Curie National Research Institute of Oncology SN/MGW18/2024
6 · The paper itself

Abstract

Borderline ovarian tumors (BOTS) are rare neoplasms of intermediate aggressiveness between cystadenomas and low-grade ovarian cancers (lgOvCa), which they share some molecular resemblances with. In contrast to the most frequent and well-described high-grade ovarian carcinomas (hgOvCa), the molecular background of BOTS and lgOvCa is less thoroughly characterized. Here, we aimed to analyze genetic variants in crucial tumor suppressors and oncogenes in BOTS (with or without the

Indexed as

Ovarian NeoplasmsAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedMutationPolymorphism, GeneticProto-Oncogene Proteins B-rafBiomarkers, TumorProto-Oncogene Proteins B-rafborderline ovarian tumorBRAFBRCA1/2DNA sequence variantNGSovarian cancerRASTP53Western blot

Identifiers

PMID39456660
PMCPMC11507582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.